Call us + 65 2324-1623

Opening Hours Mon-Sat: 9:00 AM - 5:00 PM

Address 20 Eng Hoon Street, Singapore

MCF IVF Fertility Hormonal Tests That Actually Reveal What’s Stopping Ovulation

Hormonal Tests That Actually Reveal What’s Stopping Ovulation

Ovulation depends on coordinated signals among the hypothalamus, pituitary gland, and ovaries. Hormonal tests can help identify where that signaling may be disrupted, but no single blood test reliably explains every case. The most informative evaluation usually combines menstrual and medical history with targeted tests—such as progesterone to check whether ovulation occurred, thyroid-stimulating hormone (TSH) and prolactin to look for treatable disruptions, and follicle-stimulating hormone (FSH), estradiol, and androgen testing when symptoms suggest a specific cause. The American Society for Reproductive Medicine (ASRM) defines infertility evaluation as a systematic assessment of factors affecting reproductive potential; testing should therefore be guided by the person’s symptoms and cycle pattern, not by a one-size-fits-all hormone panel.

Hormonal tests reveal different points in the ovulation pathway

Ovulation is the release of an egg from an ovarian follicle after hormonal signals prompt the follicle to mature and release it. The hypothalamus sends pulses of gonadotropin-releasing hormone (GnRH); the pituitary responds with FSH and luteinizing hormone (LH); and the ovaries produce estradiol and progesterone. A problem at any step can lead to irregular or absent ovulation. ASRM notes that irregular or absent periods are often a clinical sign of anovulation and warrant investigation.

The main test groups are ovulation-confirmation tests, pituitary and ovarian hormone tests, and tests aimed at particular causes such as thyroid disease, elevated prolactin, or androgen excess. These tests answer different questions: whether ovulation likely happened, whether the cycle’s signaling looks unusual, and whether a condition that interferes with ovulation may be present.

Progesterone: Did ovulation happen?

Progesterone is produced mainly by the corpus luteum after an egg is released. A blood progesterone measurement can provide evidence that ovulation occurred in that cycle. ASRM’s committee opinion on fertility evaluation states that a level above 3 ng/mL, measured at an appropriately chosen time, provides presumptive evidence of recent ovulation.

Timing matters more than choosing a fixed calendar day. The test is generally taken about seven days before the expected next period—not automatically on day 21, which only fits a cycle of roughly 28 days with ovulation near the midpoint. Because progesterone can fluctuate substantially over a short period, one result is not a reliable measure of “luteal quality” or of the ability to sustain a pregnancy. If cycles are irregular, a clinician may time the test based on cycle tracking or repeat it.

FSH and estradiol: How are the ovaries and pituitary signaling?

FSH helps recruit and develop ovarian follicles, while estradiol is produced by developing follicles and feeds back to the brain and pituitary. When a clinician needs to assess these hormones in relation to the cycle, they are often measured together early in the menstrual cycle, commonly on days 2–4. A high FSH alongside low estradiol can be consistent with reduced ovarian function, while a high estradiol level can suppress FSH and complicate its interpretation.

These values do not, by themselves, explain every failure to ovulate or predict an individual’s chance of pregnancy. Age, cycle timing, medication use, and the laboratory’s reference ranges affect interpretation. ASRM also emphasizes that ovarian-reserve tests are not general fertility tests: they can help estimate response to fertility medications but do not establish whether natural conception is possible.

LH: A clue to pituitary signaling, not a stand-alone diagnosis

LH is the pituitary hormone that surges before ovulation, helping trigger egg release. Urine ovulation predictor kits detect an LH rise and can help identify the fertile window, but they do not prove that ovulation followed. In some people with polycystic ovary syndrome (PCOS), baseline LH may be elevated or urine tests may show repeated positive results, so an LH result alone cannot diagnose PCOS or confirm ovulation.

A clinician may measure LH alongside FSH and estradiol when investigating absent or irregular periods. The pattern can help frame the evaluation, but results must be interpreted with symptoms, cycle history, and other tests rather than treated as a definitive label.

Cause-specific hormone tests identify common disruptions

Once a clinician has established that ovulation is irregular or absent, testing often shifts from confirming the event to looking for a cause. Thyroid dysfunction, elevated prolactin, PCOS, and reduced ovarian function are among the conditions considered. The right tests depend on symptoms: for example, nipple discharge may make prolactin testing especially relevant, while acne or excess facial hair can prompt assessment for androgen excess.

TSH: Checking whether thyroid function is affecting cycles

Thyroid-stimulating hormone is produced by the pituitary and regulates thyroid activity. Both underactive and overactive thyroid function can be associated with menstrual irregularity and reproductive difficulties. TSH is commonly used as the initial blood test for thyroid assessment; clinicians may add free thyroxine (free T4) when the TSH result or clinical picture calls for it.

The American Thyroid Association describes thyroid disorders as common conditions, with hypothyroidism affecting about 5% of people in the United States and many more having mild or unrecognized disease. A TSH result does not prove that thyroid function is the sole reason ovulation is disrupted, but an abnormal result can reveal a treatable contributor.

Prolactin: Testing when symptoms or cycle patterns point to it

Prolactin is a pituitary hormone best known for supporting milk production. When prolactin is elevated outside pregnancy and breastfeeding, it can interfere with GnRH signaling and reduce normal reproductive hormone activity. The Endocrine Society recommends evaluating for hyperprolactinemia in people with symptoms such as galactorrhea, menstrual disturbance, or infertility; it does not recommend routine screening of everyone without relevant symptoms or clinical findings.

A mildly high result may need to be repeated because stress, recent exercise, sleep, medications, and the blood-draw setting can affect levels. Persistent elevation may lead to a medication review, assessment for hypothyroidism, or further investigation of the pituitary, depending on the clinical context.

Androgens: Assessing possible PCOS and other causes

Androgens, including testosterone, are hormones that are present in people of all sexes. In someone with irregular cycles plus signs such as excess facial or body hair, persistent acne, or scalp hair thinning, clinicians may measure total or free testosterone and sometimes dehydroepiandrosterone sulfate (DHEAS). These tests help assess androgen excess and consider PCOS or, less commonly, other endocrine conditions.

The 2023 International Evidence-based Guideline for PCOS uses a combination of features—not one hormone result—to make a diagnosis in adults: ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology, with other causes excluded. In adults, two of these three features are generally required. The guideline notes that ultrasound is not necessary when irregular cycles and hyperandrogenism are already present. This prevents a hormone result or scan finding from being mistaken for a complete diagnosis.

FSH with estradiol: Evaluating possible ovarian insufficiency

When periods stop or become persistently irregular, especially before age 40, clinicians may investigate primary ovarian insufficiency (POI). The American College of Obstetricians and Gynecologists (ACOG) describes POI as loss of normal ovarian function before age 40; it can be associated with irregular or absent periods, infertility, and low estrogen. FSH and estradiol help assess the pattern, but diagnosis depends on the clinical situation and appropriate confirmation rather than one isolated result.

This evaluation matters because POI has implications beyond ovulation, including bone and cardiovascular health. A clinician may recommend additional testing or specialist referral if the history and initial hormone results support that possibility.

Test timing and clinical context determine what results mean

Hormone concentrations change across the menstrual cycle, and some results are affected by pregnancy, hormonal contraception, fertility medications, illness, or the time of day. A test result should therefore be interpreted alongside cycle dates, symptoms, medications, and the reason it was ordered. Hormone testing cannot replace other parts of an infertility evaluation, such as assessment of the uterus, fallopian tubes, and—where relevant—semen analysis.

A practical overview of commonly used tests

  • Progesterone: Often measured about seven days before the expected period to check for recent ovulation.

  • FSH and estradiol: Often measured early in the cycle when evaluating ovarian and pituitary patterns.

  • TSH: Assesses whether thyroid dysfunction may be contributing to menstrual or ovulatory problems.

  • Prolactin: Used when symptoms or menstrual history suggest excess prolactin.

  • Testosterone and sometimes DHEAS: Considered when androgen excess or PCOS is suspected.

  • LH: Can help describe pituitary signaling, but is not a stand-alone test for PCOS or proof of ovulation.

When to seek an evaluation

Consider discussing an evaluation with a healthcare professional if periods are repeatedly absent or very irregular, if there are symptoms such as unexpected milk discharge or new excess hair growth, or if pregnancy has not occurred after trying for a suitable period. ASRM generally recommends evaluation after 12 months of trying for people under 35, after 6 months for those 35 or older, and sooner when there is a known condition associated with infertility or markedly irregular or absent cycles. Individual circumstances may justify earlier assessment.

A useful appointment starts with the first day of recent periods, typical cycle length, medications and supplements, relevant symptoms, and any prior pregnancy history. Rather than ordering every available hormone test, a clinician can select tests that answer a specific question and explain what a normal, borderline, or abnormal result would mean.

Conclusion: Use targeted tests to find the reason ovulation is disrupted

Hormonal tests are most useful when each one is matched to the question it can answer. Progesterone can provide evidence of recent ovulation; FSH, estradiol, and LH help assess reproductive signaling; and TSH, prolactin, and androgen tests can uncover particular, sometimes treatable causes. No single result—including an LH ratio, a progesterone value, or an ovarian-reserve marker—explains every case on its own.

If cycles are persistently irregular or absent, bring a cycle record and symptom history to a qualified healthcare professional and ask which tests are appropriate, when they should be taken, and how the results will guide next steps. A focused evaluation can distinguish a missed ovulation from a broader hormonal condition and support timely, individualized care.

Sources: American Society for Reproductive Medicine, Fertility evaluation of infertile women: a committee opinion, https://www.asrm.org/practice-guidance/practice-committee-documents/fertility-evaluation-of-infertile-women-a-committee-opinion-2021/; American Society for Reproductive Medicine, Optimizing natural fertility: a committee opinion, https://www.asrm.org/practice-guidance/practice-committee-documents/optimizing-natural-fertility-a-committee-opinion-2022/; American Thyroid Association, General Information/Press Room: Thyroid Disease Statistics, https://www.thyroid.org/media-main/press-room/; Endocrine Society, Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline, https://academic.oup.com/jcem/article/96/2/273/2709487; Teede HJ et al., Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, https://doi.org/10.1093/humrep/dead156; American College of Obstetricians and Gynecologists, Primary Ovarian Insufficiency, https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2014/01/primary-ovarian-insufficiency.